Phase 2 N=25 Oral Testosterone for the Treatment of Hypogonadism in Males
Hypogonadism
Primary: Percentage of Responders — 67; 57; 50; 100 percentage of subjects
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=737 Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
Hepatitis C, Chronic
Primary: Percentage of Participants With Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) 24 Weeks After Completing Study Treatment (SVR24) — 86.7; 88.3 Percentage of…
Phase 3 N=182 Home-HF: Evaluation of Patients With Heart Failure Using Home Telemonitoring
Heart Failure
Primary: Days Alive and Outside of Hospital — 180; 178 Days
Phase 3 N=1,602 MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
Post Menopausal Osteoporosis
Primary: Relative Change From Baseline at One Year (12 Months) in Mean Lumbar Spine (L2 - L4) Bone Mineral Density — 3.7427; 4.3395; 4.0328; 4.7611 Percent change — p=0.045
Phase 3 N=738 Actual Use Trial of Ibuprofen 400 mg
Patient Compliance
Primary: Percentage of Participants Taking Greater Than (>) 1200 Milligram (mg) (>3 Caplets) on no More Than 2 Use Days During the Study — 95.2 percentage of participants
N/A N=18 Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection
Acute HIV Infection
Primary: Mean White Blood Cell Count Between Treatment Groups at 2 Months — 5904; 4918 white blood cells per microliter (mcL).
Phase 3 N=449 Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Seasonal Allergic Rhinitis (MK-4117-204)
Seasonal Allergic Rhinitis
Primary: Change From Baseline in Total Nasal Symptom Score (TNSS) During 2 Weeks of Therapy — -1.41; -0.59 units on a scale — p=<0.001
Phase 3 N=376 Levocarnitine in Treating Fatigue in Cancer Patients
Fatigue · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Mean Score Change in Fatigue Measured With Brief Fatigue Inventory From Baseline to 4 Weeks — -0.96; -1.11 units on a scale — p=0.57
N/A N=93 A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus Docetaxel
Neoplasms
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) in Process for the Determination of the Maximum Tolerated Dose (MTD). — 0; 1; 1; 2 Participants
Phase 2 N=34 Effects of Age on Response to the 2009 H1N1 Virus Vaccine
2009 H1N1 Influenza Virus
Primary: Number of Participants Who Shed Virus — 0 participants
N/A N=65 Study to Evaluate an Implant With a Sloped Top in Patients With a Sloped Jaw Bone
Edentulism
Primary: Bone Level Changes at the Lingual Aspect From Implant Placement (Baseline) to Re-entry 16 Weeks After Implant Placement — -0.02 mm
N/A N=516 Comparing Maintenance of Device Mastery With Turbohaler© vs. Spiromax© in Healthcare Professionals naïve to Both Devices
Asthma
Primary: Percentage of Participants Maintaining Correct Inhaler Technique for Spiromax Compared With Turbohaler 4 Weeks After Training as Assessed by Expert Assessor — 40; 64…
N/A N=152 Brief Cognitive Behavioral Therapy for Military Populations
Suicide · Suicidal Ideation
Primary: Estimated Percentage of Participants Making Suicide Attempt During 24-month Follow-up — 13.8; 40.2 estimated percentage w/ suicide attempt — p=.02
Phase 2 N=227 Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response at Week 12 (SVR12) for All Nonresponders With Genotype 1 Hepatitis C Virus (HCV) — 94.6 Percentage of…
N/A N=93 Reproductive Outcome Affected by Two Adjunctive Treatments in Patients With Severe Intrauterine Adhesions
Asherman's Syndrome
Primary: Number of Participants With Pregnancy in Loop-shaped Intrauterine Device Group and Intrauterine Balloon Group — 12; 22 participants — p=0.009